Transgenic PTTG−/− mice exhibit pituitary hypoplasia and, upon cross-breeding with heterozygous deletion of retinoblastoma (Rb+/−), show a tumor development rate of 30%. This evidence concerns the gene PTTG1 and neoplasm.